Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Outlook Therapeutics Inc OTLK

Healthcare Biotechnology
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD)... see more

Recent & Breaking News (NDAQ:OTLK)

OTLK DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK

Business Wire January 1, 2024

Outlook Deadline Alert

Newsfile January 1, 2024

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 1, 2024

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 - OTLK

Accesswire January 1, 2024

Final Deadline Alert: Bronstein, Gewirtz & Grossman LLC Reminds Outlook Therapeutics, Inc. (OTLK) Investors with Substantial Losses to Contact the Firm!

Accesswire January 1, 2024

OTLK IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

TheNewsWire December 31, 2023

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 - OTLK

Accesswire December 31, 2023

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Outlook Lawsuit - OTLK

Accesswire December 31, 2023

Final Deadline Alert: Bronstein, Gewirtz & Grossman LLC Reminds Outlook Therapeutics, Inc. (OTLK) Investors with Substantial Losses to Contact the Firm!

Accesswire December 31, 2023

INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Outlook Lawsuit - OTLK

Accesswire December 30, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK

Newsfile December 30, 2023

OTLK DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

Newsfile December 30, 2023

Outlook Shareholder Alert

Newsfile December 30, 2023

OTLK DEADLINE ALERT: ROSEN, A LEADING AND RANKED FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

TheNewsWire December 30, 2023

OUTLOOK DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Outlook Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire December 29, 2023

OTLK DEADLINE ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

TheNewsWire December 29, 2023

SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit

Accesswire December 29, 2023

Upcoming OTLK Deadline: Bronstein, Gewirtz & Grossman LLC Reminds Outlook Therapeutics, Inc. Investors with Substantial Losses to Actively Participate in the Class Action Lawsuit!

Accesswire December 29, 2023

DEADLINE MONDAY ALERT: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile December 29, 2023

OTLK DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK

Newsfile December 29, 2023